Penumbra Inc (PEN)
RBC Capital analyst Brandon Henry maintained a Buy rating on Penumbra Inc yesterday and set a price target of $174. The company’s shares opened today at $147.50.
According to TipRanks.com, Henry is a 4-star analyst with an average return of 9.1% and a 68.6% success rate. Henry covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Edwards Lifesciences, and Integra Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Penumbra Inc with a $175 average price target, which is a 18.6% upside from current levels. In a report issued on August 1, Wells Fargo also reiterated a Buy rating on the stock with a $185 price target.
RBC Capital analyst Kennen MacKay maintained a Hold rating on Regeneron on August 6 and set a price target of $399. The company’s shares opened today at $303.12, close to its 52-week low of $287.66.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 11.9% and a 53.1% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Akebia Therapeutics, Puma Biotechnology, and Seattle Genetics.
Currently, the analyst consensus on Regeneron is a Hold with an average price target of $375.11, representing a 23.7% upside. In a report issued on July 30, Cowen & Co. also assigned a Hold rating to the stock with a $353 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.